May 13, 2020Open Access

Atezolizumab plus Bévacizumab dans le carcinome hépatocellulaire non résécable

Key Points

Key points are not available for this paper at this time.

Abstract

Chez les patients atteints de carcinome hépatocellulaire non résécable, l’association d’atezolizumab et de bévacizumab a entraîné de meilleurs résultats en termes de survie globale et de survie sans progression que le sorafénib. (Financé par F. Hoffmann-La Roche/Genentech ; numéro ClinicalTrials.gov, NCT03434379.).

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Richard S. Finn

Shukui Qin

Masafumi Ikeda

Journals

New England Journal of Medicine

Actions

Institutions

Harvard University

Massachusetts General Hospital

The University of Texas MD Anderson Cancer Center

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Atezolizumab plus Bévacizumab dans le carcinome hépatocellulaire non résécable

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study